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Abstract

Treatment options and duration of therapy for patients with metastatic renal cell carcinoma (mRCC) have increased.
Many patients now spend in excess of 2 years on active therapy. These patients’ needs, and the ability of health services
to respond to them, are poorly understood. Ten patients living with mRCC for more than 2 years and treated with at
least one targeted agent were selected at random from three hospitals in the United Kingdom (UK). One interviewer
who was not involved in their care conducted in-depth interviews. Interview transcripts were analysed using
Interpretative Phenomenological Analysis (IPA) to identify issues of greatest importance to patients, and to understand
how well patients felt their needs were being addressed. Perceived delay in initial diagnosis was a major theme. Being
told the truth about treatment side effects upfront was important, but was often at odds with perceived delivery.
‘Dealing with side effects’, understanding dose and its effects and not letting ‘negative thoughts get in’ were highlighted
as important, but were highly personal to patients and areas where patients struggled. Concordance was observed with
delivery of ‘a clear next step’ for treatment, timely access to drugs and guidance on a drug ‘holiday’. Patient experience of
mRCC and its treatment requires a tailored approach. This research suggests there are key opportunities for service
improvement and improved communication throughout the pathway to better meet the needs of patients, including
non-clinical support to build personal resilience.
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Introduction
Kidney cancer is the 8th most common cancer in the UK,
affecting almost 10,000 patients per year, and incidence
has been increasingly rapidly1. At diagnosis, approximately
20-30% of renal cell carcinoma (RCC) patients will have
metastatic disease. Of those presenting with localised
disease at diagnosis, up to 30% will go on to relapse with
distant disease2.
The prognosis for this group of patients with advanced
disease has historically been poor. Cytokine therapies have
been commonly used in the treatment of metastatic renal
cell carcinoma (mRCC) but with anti-tumour effect limited
to relatively few patients. Interferon-α (IFN-α) has an
approximately 11–15% objective response rate in
appropriately selected individuals3. Historical median
survival has been around 14 months in patients treated
with IFN-α.

But while there is much emphasis on improving patient
care in this setting, and while some research has been
undertaken into the needs of patients and their caregivers
across a range of cancer types6, there has been little focus
specifically on patients with mRCC7. Given the specific,
and very recent, changes to the treatment of mRCC and
the potential for significantly improved patient outcomes
that these bring, it is important to fully explore whether
the needs of this group of patients are currently being
addressed.

In recent years, there has been a rapid expansion of
treatment options for these patients. Two classes of
agents, anti-angiogenic agents targeting vascular
endothelial growth factor (VEGF) and other pathways,
and mammalian target of rapamycin (mTOR) inhibitors,
have been licensed across various lines of therapy giving
patients more generally efficacious treatment options. It is
now possible to treat patients beyond three lines of
effective therapy.

The health and social care services previously organised
and designed to look after these patients may no longer be
fit for purpose, and patients may not have access to wider
support and services outside the clinic environment.
Increasing numbers of patients will be using services for
longer, and the nature of the disease and the side effects of
treatment have changed.

This step change in the outcomes that can be expected for
patients presenting with mRCC has resulted in many more
patients surviving longer with this disease. Moreover,
unlike traditional chemotherapy regimens, these newer
treatments are typically orally administered and are taken
on a continuous basis while the patient continues to get
benefit. Patients are now taking more targeted therapies at
home in pill or capsule form. Once they have adjusted to
their new treatment, many return to a good level of
function, and some may return to work. In practice, little is
known about the needs of people managing their life with
advanced disease in this way, and whether these needs are
being correctly identified and met.
In England, the Department of Health (DoH) has
previously acknowledged the importance of identifying
and meeting the needs of patients who are still living with
their cancer alongside those who have had successful,
curative treatment. This led to the creation of the National
Cancer Survivorship Initiative (NCSI), a key part of the
DoH’s Cancer Reform Strategy when it was published in
2007. Survivorship has been retained in the more recent
DoH publication ‘Improving Outcomes: A Strategy for
Cancer’4 with UK charity Macmillan Cancer Support, also
known as Macmillan, as a key delivery partner.
Recently, the importance of patient experience has been
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further enshrined in the National Health Service (NHS)
Outcomes Framework for 2013/145, particularly at the
end of life (defined as the final three months of life), with
improving the experience of care for people at the end of
their lives being stated as a priority for the NHS in
England. Additionally, the NHS Outcomes Framework
requires the NHS to strive to enhance the quality of life
for patients living with long-term conditions, and to
enhance quality of life for their caregivers.

The current study aims to understand the needs of patients
living longer term with metastatic renal cell carcinoma and
to explore how well patients perceive their needs are being
met by current services.

Patients and Methods
Participants

Ten patients attending renal clinics at The Christie
Hospital (Manchester), Bart’s and the London NHS Trust
(London) and The Beatson West of Scotland Cancer
Centre (Glasgow) were enrolled into the study. These
participants were adults with stable mRCC diagnosed
more than 24 months previously and who had been
treated with one or more targeted therapies (including but
not limited to sunitinib, sorafenib, pazopanib,
bevacizumab, temsirolimus or everolimus). Initial entry
criteria had included an upper limit of 36 months of
treatment, but this criterion was removed during the study
to facilitate recruitment. Participants were capable of
giving informed consent to participate and of undergoing
face-to-face interviews with investigators, either
independently or through translators.

Methods

Interpretative phenomenological analysis (IPA), the key
methodologies of which have been described elsewhere8,
was employed in this study. Subjects underwent a single,
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one-to-one semi-structured interview, lasting typically
between 60 and 90 minutes. Nine subjects were
interviewed in their own home by the chief investigator,
one by telephone. Consent was obtained to audio-record
each interview in full so that the detailed line-by-line
analysis of every conversation could be achieved.
The outline structure for the interviews was derived from
extensive analysis of the literature carried out between
December 2010 and January 2011. In particular, grey
literature such as patient Internet chatrooms and for a
dedicated to kidney cancer were included in the search.
These sources were analysed similarly to the patient
interviews (see below) and likely emerging themes were
identified. Using these expected emerging themes, the
interviewer was able to provide direction for the
conversation if required. Moreover, the themes identified
as likely to emerge from the review of the literature could
be compared to areas proactively raised by patients during
the interviews. Themes predicted to arise from the
literature review prior to the interviews, and those
summarised in Table 1. Open-ended questions were used
to facilitate discussion, but the interviewees were free to
tell their story in their own way.

Data Analysis
The Chief Investigator, who moderated the interviews,
and a second researcher who completed an independent
analysis carried out data analysis. IPA moderators are
trained to suspend presuppositions and judgment whilst
reading the text transcripts, in order to focus on what is
actually presented in the transcript data. This involves the
practice of “bracketing”9 – the suspense of critical
judgment and a temporary refusal of critical engagement,
which would bring in the researcher’s own assumptions
and experience10. However, IPA acknowledges a role for
interpretation. Therefore, once the initial data analysis is
done, the moderator conducts a second pass, adding their
interpretation of the meaning of the data. This is then
integrated across the two assessments of moderator and
secondary researcher. Two complementary approaches
were employed; thematic analysis and case study analysis.
The thematic analysis aimed to identify and code key areas
of importance arising from the interviews, focusing on
participants’ experiences of the care they received. All
interviews were transcribed in full to facilitate analysis.
Each transcript was then manually coded, with the
researchers creating a label for each patient comment,
primarily regarding their experience and perspective of an
issue. Line by line labeling of the transcript ensured all
data were captured for the analysis. The researcher,
providing interpretation of the meaning of the patient’s
comment, then added a further comment.
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From these detailed codes, higher-level themes were
established, aggregating similar experiences together,
and phrased in the first person in order to represent a
participant speaking. In addition, a further 'tag' was added
which identified when in the patient’s treatment pathway
the issue occurred (e.g. at diagnosis).
For example, the following excerpt was labeled Panic &
Rationalisation and fell into the ‘Diagnosis’ point in the
patient pathway:
“They wanted to put me through a scan … could my daughter get my
wife up there? I thought 'that was not sounding clever'. They kept
me in … The doctor came up and said "we can't deal with you in
this hospital, we have got to send you to [another hospital]". …
"why can't you deal with it?" He said "because this is not lung
cancer, this has come from your kidney". I thought 'Oh No!'’’
The themes emerging from the interviews were then
compared against the themes which were expected to
emerge from the pre-work to identify any areas which
were discussed previously in the literature, or are the focus
of discussion on online support groups, but which were
not raised by interviewees in this study (Table 1).
To determine how important each theme was, and how
well current provision met the expectations of patients for
this theme, all comments relating to each theme were
grouped and assessed in the context of all the issues rose.
Where the same theme was raised repeatedly both within
and across interviews, researchers interpreted this as of
higher importance than those raised less frequently. For
example, if all patients stated a need for early diagnosis,
this was rated as more important than if only one patient
made the comment. In addition, researchers sought to
interpret the intensity of the issue rose. This was
ascertained from a range of 'clues' including the type of
language used and degree of emphasis placed. For
example, high intensity was ascribed to an excerpt using
words such as "terrifying" and "extremely worried". In
this way, an issue that was of extreme importance to a few
patients would be considered of similar importance to an
issue raised by all patients, but without the same intensity.
Finally, using case study analysis, consideration was given
as to how well each theme was delivered against by the
current service and other sources. Where participants
described their symptoms as not being recognised, a low
level of 'delivery' was interpreted. For example, "I started
getting pains round about my kidney area in my back. I
went to the doctor a few times, and she kept saying it was
an infection and different things".
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Table 1: ‘Pre-fieldwork’ shows the list of themes arising from desktop research and a literature review,
including patient fora and chatrooms dedicated to kidney cancer. This informed the discussion guide
(Table 4) for use in the patient interviews. ‘Post fieldwork’ shows the themes that were actually raised in
the patient interviews. The four final high-level themes were plotted as ‘journey steps’ on the lifeline
(Figure 2).
Pre-fieldwork

Post-fieldwork

Symptoms and RCC diagnosis
1. No obvious symptoms
2. Confusion and disbelief - where did it come from?
3. Diagnosis comes out of the blue and is devastating
4. A death sentence - panic sets in
5. Playing with statistics

Symptoms and RCC diagnosis
1. Out of the blue with no obvious symptoms
2. Panic and rationalisation

Getting over the shock and seeking options
6. A waiting game
7. Limited options
8. Getting informed and taking some control
9. Craving normality
10. No silver bullet or miracle cure

Getting over the shock and seeking options
3. Getting immediate attention
4. A plan of action
5. Getting the right information I can trust
6. Facing reality and acceptance

Surviving mRCC
11. A rollercoaster of emotions - coping with the
constant ups and downs
12. Extending life and precious time
13. Life appreciation and 'bucket' lists
14. A constant fight - ready for the next hit
15. A different person
16. Clutching at glimmers of hope
17. Shared experiences and deep connections
18. Enduring the treatment and side effects - not giving
up
19. Having a wellness plan
20. Financial burden
21. Family impact and support

Finding ways to cope
7. Ups and downs & complications
8. Time matters
9. A different normality
10. Coping day to day
11. A different person
12. Side effects, effectiveness and quality of life
13. Work and financial implications
14. Support around you

On-going monitoring
22. Running out of options
23. Scanxiety - dread of mets

Keeping stable
15. Prepared to try anything and everything
16. Size matters (tumour)
17. Drug reliance and routine
18. Constancy of care

Impending final days
24. Fighting to the end
25. What you want, not what others expect
26. Submission
A visual illustration of the higher level themes and
patients’ experience of delivery against these was then
developed, with themes placed chronologically from
before diagnosis to present time on the ‘lifeline’ chart (see
Figure 1).
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Results
10 patients were enrolled into the study with equal
numbers of men and women and an average age of 64.
Basic demographics for the patients, including date of first
diagnosis and their initial treatment for metastatic disease,
are presented in Table 2.
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Emerging topics and themes

As can be seen from Table 1, the themes which arose from
both the pre-work and the interviews could be grouped
into areas which formed a patient journey from initial
symptoms and seeking help, through diagnosis and
treatment and ultimately to discussions about end of life.
But while the broad topics were consistent, 5 of these
emerged in the pre-work, with only 4 emerging from
interview, and the detailed themes which emerged differed
between the pre-work and interviews in several areas.
Some of the pre-fieldwork themes were more desperate
and fatal in tone than those arising in the interviews. The
expected narratives of ‘a death sentence’, ‘limited options’,
‘fighting to the end’ and ‘submission’ were either reduced
in their intensity or absent. Themes were more day-to-day
in emphasis with patients generally on a more even keel,
albeit reporting ‘ups’ and ‘downs’.
The first two topics, ‘symptoms and RCC diagnosis’ and
‘getting over the shock and seeking options’ were very
broadly consistent between the pre- work and the
interviews. However, the next phase was described
following the pre-work as ‘surviving mRCC’, with some
emphasis on extending life and fighting cancer. This was
altered after the fieldwork to ‘finding ways to cope’ with
the interviewees talking much more about coping day-to-

day and finding a new normality more than fighting
cancer.
In the pre-work, the 4th and 5th topics were ‘ongoing
monitoring’ and ‘impending final days’. The pre-work
identified a period where patients were anxious about
scans, and about running out of treatment options, before
a final stage where patients discussed end of life, death and
dying. During interviews, this 4th stage was much more
about stability, both of tumour size on imaging as well as
treatment regime. Fear of running out of options had
been a major identified theme in the pre-work; a theme
which did not emerge during the actual interviews.
Pre-work ahead of the study identified a 5th topic, dealing
with death and impending final days, as being of
significant concern to patients with RCC and there is
much discussion, particularly in online support groups,
about fear of death in particular. When analyzing this
study’s results, it became clear that needs around death
and dying are reflected in research conducted by
Macmillan that led to the inclusion of ‘I want to die well’
in Macmillan’s 9 outcomes, a series of nine statements that
the charity developed with cancer patients and which they
want every patient with cancer to be able to say by 2030 11
(see Table 3). Interestingly, patients did not raise death or
dying in this study. The methodology used here did not

F
igure 1: The patient lifeline. Issues highlighted as important are grouped chronologically from left to right according to where
they affect the patient during their treatment. How important these issues are (blue line) is graphed against how well the
issues are being met (yellow line). Larger gaps between the lines suggest areas where the most work needs done to meet
patient needs.
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Table 2: Baseline characteristics of the included patients
Participant

Gender

Age

Lead mRCC Treatment

Date of mRCC diagnosis

1

Female

74

sunitinib

Mar 2009

2

Female

60

sunitinib, interferon

Jan 2009

3

Male

60

pazopanib

May 2011

4

Male

62

sunitinib

Jun 2010

5

Female

55

sunitinib, radiation

Jan 2010

6

Female

66

pazopanib

Sep 2010

7

Male

74

pazopanib

Jan 2011

8

Male

68

pazopanib

Jul 2010

9

Female

62

sunitinib

Feb 2010

10

Male

66

sunitinib

Dec 2010

Table 3: Macmillan’s 9 outcomes, a series of 9 statements that the UK charity Macmillan Cancer Support report that
cancer patients want to be able to say in relation to their diagnosis and care.
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include proactively raising specific issues which were not
raised by patients, so it is not clear what drove this lack of
willingness to raise death in this forum.

Lifelines

The lifelines chart (Figure 1) takes the topics and emerging
themes and displays them along with graphic
representation depicting how important these issues were
to the interviewed patients (blue line), and how well they
were delivered to the patient (yellow line).
All of the issues listed are of importance to patients.
Interestingly, in a large number of areas, the care,
information or support that the patient received did not
meet with their needs, as can be seen from Figure 1. The
largest gaps between importance and under-delivery were
observed in the following areas:
 Early diagnosis in order to have more options
 Coping with side effects through treatment
 Staying positive through the ‘down cycle’, or
psychological or physical low points during
treatment
 Understanding dosage and effects for them
 Being prepared for the possibility of side effects.
However there was significant under-delivery in a range of
other areas including: connecting their diagnosis with
symptoms; being told the truth about treatment; an
explanation of who there is to talk to, including outside the
clinical team; personal goal setting; reaching for special
moments; finding positives every day; gaining help with
imposed restrictions, such as travel insurance; and making

the best of any time off treatment.
In very few areas did delivery of care match or exceed the
expectations of the patients. The value of Macmillan in
helping access financial benefits and the value of other
professional support (when accessed) were two such areas,
as were getting the right drug when needed, being given
treatment breaks where necessary, being told about
changing tumour size and a relationship with the whole
team, not just the consultant.
For the first main topic, diagnosis, of particular concern is
that under-delivery started even before a diagnosis. The
patients in this study highlighted a failure to connect the
symptoms with which they had been suffering to their
eventual diagnosis, and were upset that the late diagnosis
left them with few options for treatment, and no prospect
for cure.
The second main topic identified in this study was ‘getting
over the shock and seeking options’. At this point, the
participants of this study required a clear next step, and a
plan of action delivered with sensitivity. Overall, these
requirements were met for the patients in this study,
No patient in the sample cohort proactively raised wanting
to use the internet to access comprehensive details of their
condition. However, most wanted a simple, truthful
explanation of their condition, their prognosis, and a clear
next step, as well as a recommendation from their
consultant as to the best course of action. Patients also
wanted to feel involved, and to have all the facts about
their cancer provided. In particular, patients in this study
wanted to see scans and ‘make it tangible’. The delivery of

Figure 2: The relative proportions of time individuals feel like a ‘patient’ compared with feeling more normal (like a
‘person’).
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the above was not provided consistently, but elements of
each were reported.
Macmillan nurses were highly valued for support at this
stage, even if their initial appearance at diagnosis was
feared by loved ones as a sign of more significant disease.
One patient stated “The first I really heard of it was when I read
the piece of paper and I saw the word ‘tumour’. I thought ‘I hope
there is not a Macmillan nurse there’, and this other woman walked
in and she has got a Macmillan nurse and I thought ‘oh shit’. I was
in almost blind panic then”

‘Patient’ or ‘Person’?

‘Finding ways to cope’ was a major topic in this study.
The themes, which patients identified as important under
this topic, were a mixture of external (such as being well
prepared by hospital staff for the side effects of medicines)
and internal (such as finding something positive in every
day or not letting negative thoughts in). The participants
in this study very consistently identified a balance between
patient and person as being important for them in finding
ways to cope. Patients varied during their treatment as to
where this balance lay for them, but there was even greater
variation between patients as to where they spent the
majority of their time (Figure 2). The extremes of this
spread are summarised by two patient quotes. Patient 1,
who feels like a ‘patient’ the majority of the time, stated,
‘Now the side effects and treatment are worse than the cancer itself.
Not long-term of course, but on a living my life day-to-day level,
much, much worse. I’m on treatment and oh boy … then it’s just
about getting through each day of the cycle and to the end of it, to feel
whole again.
It makes me feel like two people. One who’s fine, normal, human –
the old me; the other one who’s really sick and has a terminal disease
and there’s no going back …’.
In contrast, patient 8 managed to find more of a positive
balance, claiming to feel more like a ‘person’ than a
‘patient’ for the majority of the time. Patient 8 stated, ‘Yes
I have cancer but I just don’t let it get to me. I’m not the only one
and I don’t want to waste my life feeling sorry for myself. I’m lucky
actually – I have my husband, children and grandchildren. They keep
me going.
It’s about living day by day but also setting targets. Like when we
celebrated our 45th wedding anniversary.
They told me the outlook was not good – maybe a year. Well that
was 3 years ago so I’ve beaten that so what’s stopping me now?
Yes sometimes the side effects can be inconvenient but nothing worse
than other illnesses. There are some things I can’t always do or need
help with but then I’m not getting any younger anyway’.
Patients described the importance of setting personal
goals, finding something positive to focus on, starting the
day positively and avoiding negative thoughts. But
patients were not always able to achieve this. Patients in
this study were conscious that treatment optimization, and
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especially optimization of drug dosage, are key to
achieving tumour control but also impact side effects. By
balancing control of disease effectively against presence of
side effects, patients were best able to define themselves as
a ‘person’, rather than a ‘patient’ for more of the time, and
this definition of self as ‘person’ was a key to remaining
positive.
Those patients that had developed a trusting relationship
with their clinic nurse in particular felt most engaged in the
achievement of such balance. In particular, some nurses
would suggest a ‘drug break’ if they felt that the patient
would benefit from a relief or freedom from side effects
for a period of time. Some patients were wary of coming
off a treatment that was limiting tumour growth, but
recognised that their endurance of side effects had its
limits. Set against this balance, patients felt the nurse best
identified the consideration of a drug break.
Few patients in this study turned to professional care
support services on a regular basis. Instead, most turned to
their spouse and occasionally children to provide care, not
just for functional help but moral support, and simply to
provide company. Some mentioned that having access to
friends (non-family) to be able to discuss non-clinical
issues (sport, hobbies, current affairs) provided a welcome
distraction from introspection towards their condition.
Few individuals mentioned being able to obtain support
from the wider RCC community, and indeed some actively
did not want to reach out to such a community.
Where professional external organisations did add
significant value was in support for managing finances,
such as getting access to entitled benefits. In particular,
Macmillan was praised for helping patients access the
benefits they were entitled to. This was important to
patients, who described issues of work, and the financial
pressures of not being able to work, as being of particular
concern to them and their families. The role of an
employer was often key. Some were described as
exemplary in offering flexibility and support, whilst others
added to the stress, with patients needing personal legal
support to settle their employment situation. Advice and
support for dealing with employers was very difficult to
come by, and would be welcomed by patients.
The balance of factors exerting their effects on patients
drove this variation between patients, and the extent to
which the patient or the person predominates. These
were:
 Patient disposition (optimist or pessimist,
resilience)
 External factors, such as family support, financial
concerns, existence of dependents, etc.
 The amount of focus on the malignancy
 Treatment cycle and especially side effects

Patient Experience Journal, Volume 2, Issue 2 - Fall 2015

Patient needs in advanced Renal Cell Carcinoma, Harris et al.


External events, such as Computed Tomography
(CT) scan results.

Of these, the impact of toxicity was, in this study,
particularly high, but also very variable. This was true
whichever of the two medicines were used, but we have
focused on the 6 patients who received sunitinib to
demonstrate that variability.
Of the patients on sunitinib, patient 10 had relatively little
toxicity, and showed little fluctuation in mood over the 6
week cycles. Patient 9 had more toxicity, and cycled
between feeling like a ‘patient’ during the 4 weeks on
treatment, and feeling more like a ‘person’ during the two
weeks off. Finally, patient 1 had toxicity which they
perceived very negatively, such that the negative impact
extended even into the off treatment period, resulting in
ongoing anxiety about restarting treatment.
The final topic of concern to patients was ‘keeping stable’.
This applied both to mood and to the tumour size and
clinical response. Patients valued drug holidays where
possible to help offset side effects, as well as close
relationships with the whole of the multi-disciplinary
clinical team to help them feel they were getting access to
the best advice in a timely manner. Again, a theme that
emerged in this topic was that of being told honestly about
how the tumour was doing, and even being shown the
scans if possible. Tumour size and stability was perceived
by patients as both a tangible measurement of stability as
well as easy to present and understand in lay terms. In this
study, patients felt very included in their management and
were extremely appreciative of this involvement.

Discussion
The treatment environment for mRCC is changing rapidly,
but the impact of these changes on patients’ needs and
expectations, and how well these are met in practice, has
been poorly studied.
The current study was designed to use in-depth interviews
with patients, assessed using IPA, to understand the needs
of patients living long-term with mRCC, and to explore
their perceptions of how well these needs are being met.
In addition, the authors sought to explore attitudes to any
external support services and networks, and how and
where such services could be improved.
Poor RCC outcomes in the UK is a particular concern,
with only two countries in Europe (Denmark and
Bulgaria) having a lower 5 year survival12. Among
proposed explanations is late diagnosis in primary care,
and this study certainly appears to add some weight to that
theory. With the incidence of kidney cancer rising so
quickly, it is imperative more is done to educate primary
care physicians and members of the public on the need to
seek expert advice for persistent suggestive symptoms. In
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analyzing the study results, some progress has been made
with the commissioning of national campaigns to increase
public awareness and encourage presentation in primary
care13.
The diagnosis of RCC is one that comes with quite
significant shock to patients. A strong and effective multidisciplinary team, including excellent nursing support, is
crucial to delivering a ‘clear next step’ and a plan of action
clearly, simply and sensitively, as this had a direct impact
upon the patients’ ability to develop coping mechanisms.
Such a team could also equip patients to prepare earlier,
including developing an understanding of side effects, and
discussing options for dealing with them.
As the role of the Macmillan nurse is reported to be very
important, perhaps more could be done to introduce the
Macmillan nurse in such a way as to mitigate some of the
fears that patients associate with this job title. This fear
may also lie behind the decision of some patients not to
utilise the nurses’ services from the start but patients
valued being aware of them. If and when the need to use
them came, speed of delivery was essential (and was
reported to be excellent).
A significant focus of patients in this research was
characterised by ‘finding ways to cope’. It was under this
topic in particular that the major themes identified as
important to patients were least well delivered against.
At the time of the pre-work, there were no routinely
available treatment options for patients whose disease had
progressed on first line sunitinib or pazopanib in the UK.
In the time between the pre-work being conducted and the
study opening to recruitment, further treatment options
became available to patients. It would be worth exploring
further what psychological impact limited access to
treatment has on patients in the current climate of
budgetary restrictions and restricted medicines access.
Regular treatment breaks associated with sunitinib
appeared to help participants in this study establish a
better balance between ‘patient’ and ‘person’. This
observation could lend support to the exploration of
regimens, which include planned treatment breaks such as
permitting ‘drug holidays’ (where patients with on-going
clinical benefit from a drug discontinue the drug only to
restart the same treatment when there is evidence of
disease progression). One such study is underway in the
UK14.
It is interesting to note that whether or not they were
delivered against, eight out of nine Macmillan patient
outcomes statements, which have been developed with
patients who have a form of cancer, would certainly
appear to be applicable to the patients in our study. There
was a lack of expressed desire to be part of a wider cancer
community and the statement ‘I feel part of a community
and I’m inspired to give something back’ was not
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Table 4 – Discussion Guide
PART 1: INTRODUCTION
Introductory Statement:
Our discussion today is really all about your personal experience of living with ……
One of the topics we’re likely to cover is your experience of medicines, including any possible side-effects you may have
experienced. Should this happen, we are required to report these details to the sponsor of our study, who is a manufacturer of
medicines. This is so that they can learn more about the safety of their medicines, esp. as some side effects may not be
discovered until many people have used a medicine over a period of time. Everything else we discuss today will be treated in
confidence and made anonymous – it is solely if you mention a side effect you, or someone you know, has experienced. Are
you happy to proceed with the interview on this basis?’ [If yes] – So, we have a little bit of paperwork to complete before we
start, with a few statements to read, and you’ll find one of them talks about “adverse events” – this is what healthcare
professionals tend to call side-effects.
Establish rapport:
how are you feeling today?
How has your day been so far?
PART 2: YOUR EXPERIENCE
1. Can you tell me about how this all began?
PROMPTS: early signs or symptoms? Explanations to yourself? Your awareness?
Where did you look for information / advice / help?
2. And from that point of awareness, how did you get to a point of getting a diagnosis?
PROMPTS: length of time, stages described, accuracy
3. What was your experience of doctors and the medical profession at the diagnosis stage?
PROMPTS: What was good, what was bad? What would have helped?
4. What can you tell me about your thoughts and emotions after diagnosis?
PROMPTS: sharing the news with family and friends, other relationships, work and other roles
5. At that stage what were your priorities?
PROMPTS: longevity, quality of life, alleviating symptoms, gaining control
6. What were your thoughts and feelings about treatment or treatment options?
PROMPTS: role of medical practitioners, treatment centres, managing symptoms, dependency on treatments, what is
good, what is bad?
7. What are your thoughts about keeping going with the treatments?
PROMPTS: motivation? Influences? What would help improve treatment?
8. Can you describe day-to-day living for me a little? The ups-and-downs?
PROMPTS: what makes for a good/bad day? Missing from the past? Expectations? Emotions?\
9. Aside from the physical changes, to what degree do you think living with your condition has changed you as a person?
PROMPTS: your attitude / character? Outlook? Relationships? Gained/lost? Have changes been slow, steady, sudden?
10. What helps you cope with everyday life?
PROMPTS: Adaptions, coping mechanisms? Identified by? (trial/error, advice)
11. And can I ask what areas of life are more difficult to cope with? What are the things that you would most want to
improve / recover more normality of?
PROMPTS: Activities, family/relationships, ambition/achievement
LOOKING FORWARD
11. What are your priorities now? And for the future?
PROMPTS: Longevity, well-being, wellness plan, financial planning/mgt, alleviation of symptoms etc.
THANK AND CLOSE
Table 4: The above discussion guide with thematic prompts was used to aid structure within the conversation, without
restricting or leading the interview flow unnecessarily. The discussion guide was not used as a set of questions to be
systematically asked. Instead, it was used flexibly, supporting the participant to tell their own individual story, and the
moderator to be an ‘active listener’. Prompts were used where the interview lacked its own spontaneous course and to help
establish rapport and rhythm to the interview. IPA methodology encourages the participant to set the parameters of the
discussion and to follow the path of their own experience. This is key, as a predetermined set of criteria may not all have been
relevant for each of the 10 participants.
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articulated by our patient group as important, and perhaps
should be reconsidered by Macmillan.
Caution should be exercised before extrapolating our
findings to the broader cancer population, or indeed the
broader mRCC population. The patients studied here were
from a sizeable group of outliers in that, for the most part,
they had significantly exceeded ‘average’ life expectancy
from this disease and had been on treatment for
significantly longer than the average duration. This may
well have impacted on various observations – for example,
the failure of these patients to pro-actively raise the issues
surrounding terminal care may reflect the fact that these
patients were all some distance from the time of initially
being told of their terminal prognosis, and none of them
were imminently entering the terminal stage of their
illness. It is quite possible that a group of patients who
were experiencing an altogether shorter journey from
diagnosis to death would have put much greater emphasis
on this aspect. Conversely, the effects of chronic treatment
side effects are likely to be of higher impact in the
population studied here.
Given the variation that exists, the care and treatment of
patients with mRCC needs to be individualised not only in
relation to drug treatment but the targeting and provision
of information, and of clinical and non-clinical support
services. Further work to understand how best to assess
the changing needs of patients with mRCC over time
could prove valuable.

Summary

4.

5.

6.
7.
8.
9.
10.
11.

The current study provides rich insight through individual
patient narratives into the many challenges which the
welcome improvement in renal cancer outcomes have
provided in recent years.

12.

The lifelines chart demonstrates which issues are
important to patients, and provides good insight into
where their important concerns are, or are not, being met.

13.

References
1.

2.

3.

CRUK. Kidney Cancer Statistics. CRUK [ 2013 [cited
1013 Nov. 14]; Available from:
URL:http://www.cancerresearchuk.org/cancerinfo/cancerstats/keyfacts/kidney-cancer/
Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z.
Patterns of failure following surgical resection of renal
cell carcinoma: implications for adjuvant local and
systemic therapy. Journal of Clinical Oncology [ 1994
12:[206-212]
Tsui KH, Shvarts O, Smith RB, Figlin RA, et al.
Prognostic indicators for renal cell carcinoma: a

Patient Experience Journal, Volume 2, Issue 2 - Fall 2015

14.

multivariate analysis of 643 patients using the revised
1997 TNM staging criteria. Journal of Urology [ 2000
163:[1090-1095]
Department of Health. Improving outcomes, a
strategy for cancer. 2011 Available from:
URL:http://www.dh.gov.uk/prod_consum_dh/grou
ps/dh_digitalassets/documents/digitalasset/dh_1233
94.pdf
Department of Health. The NHS Outcomes
Framework 2013/14. 2013 Available from:
URL:https://www.gov.uk/government/uploads/syst
em/uploads/attachment_data/file/213055/121109NHS-Outcomes-Framework-2013-14.pdf
Cancer Survivorship Ingrid Ingrid Torjesen. (2010) 25
March 2010 Health Service Journal supplement, 1-3
Researching the experience of kidney cancer patients
K Taylor. (2002) European Journal of Cancer Care
11, 200–204
Smith JA, Osborn M. Interpretative
Phenomenological Analysis. Qualitative Psychology.
Sage Publications UK; 2007. 53-80.
Husserl E. Ideas I. In: Welton D, editor. The essential
Husserl: Basic writings in transcendental
phenomenology. Indiana University Press; 1999.
Spinelli E. The mirror and the hammer: challenging
orthodoxies in psychotherapeutic thought. Sage
Publications UK; 2002. 32.
Macmillan Cancer Support. Improving cancer patient
experience - a top tips guide. 2012 Available from:
URL:http://www.macmillan.org.uk/Documents/Ab
outUs/Commissioners/Patientexperiencesurvey_Top
tipsguide.pdf
Angelis RD, Sant M, Coleman MP, Francisci S, Baili
P, Pierannunzio D et al. Cancer survival in Europe
1999-2007 by country and age: Results of
EUROCARE-5 - a population based study. The
Lancet Oncology 2014; 15(1):23-34.
Cancer Research UK (CRUK). 'Blood in Pee'
campaign. (2014) Available from: URL:
http://www.cancerresearchuk.org/healthprofessional/early-diagnosis-activities/be-clear-oncancer/blood-in-pee-campaign
Collinson FJ, Gregory WM, McCabe C, Howard H,
Lowe C, Portrata B et al. The STAR trial protocol: a
randomised multi-stage phase II/III study of sunitinib
comparing temporary cessation with allowing
continuation, at the time of maximal radiological
response, in the first-line treatment of locally
advanced/metastatic renal cancer. BMC Cancer
12[598]. 2012.

152

